Treatment of Prostate Cancer With Intermittent Versus Continuous Androgen Deprivation: A Systematic Review of Randomized Trials

被引:90
|
作者
Niraula, Saroj [1 ,2 ]
Le, Lisa W. [3 ,4 ]
Tannock, Ian F. [3 ,4 ]
机构
[1] CancerCare Manitoba, Winnipeg, MB R3E 0V9, Canada
[2] Univ Manitoba, Winnipeg, MB, Canada
[3] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[4] Univ Toronto, Toronto, ON, Canada
关键词
PHASE-III TRIAL; HORMONAL-THERAPY; SUPPRESSION; IMMEDIATE; FINNPROSTATE; EORTC; RISK; MEN;
D O I
10.1200/JCO.2012.46.5492
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Uncertainty exists regarding benefits of intermittent androgen deprivation (IAD) compared with continuous androgen deprivation (CAD) for treatment of prostate cancer. On the basis of a systematic review of evidence, our aim was to formulate a recommendation for either IAD or CAD to treat relapsing, locally advanced, or metastatic prostate cancer. Methods We searched literature published up to September 2012 from MEDLINE, EMBASE, the Cochrane Library, and major conference proceedings. We included randomized controlled trials comparing IAD and CAD if they reported overall survival (OS) or biochemical/radiologic time to disease progression. Results Nine studies with 5,508 patients met our criteria. There were no significant differences in time-to-event outcomes between the groups in any studies. The pooled hazard ratio (HR) for OS was 1.02 (95% CI, 0.94 to 1.11) for IAD compared with CAD, and the HR for progression-free survival was 0.96 (95% CI, 0.76 to 1.20). More prostate cancer-related deaths with IAD tended to be balanced by more deaths not related to prostate cancer with CAD. Superiority of IAD for sexual function, physical activity, and general well-being was observed in some trials. Median cost savings with IAD was estimated to be 48%. Conclusion There is fair evidence to recommend use of IAD instead of CAD for the treatment of men with relapsing, locally advanced, or metastatic prostate cancer who achieve a good initial response to androgen deprivation. This recommendation is based on evidence against superiority of either strategy for time-to-event outcomes and substantial decrease with IAD in exposure to androgen deprivation, resulting in less cost, inconvenience, and potential toxicity. (c) 2013 by American Society of Clinical Oncology
引用
收藏
页码:2029 / U342
页数:9
相关论文
共 50 条
  • [41] Androgen deprivation treatment in prostate cancer
    Thomas, Benjamin C.
    Neal, David E.
    BMJ-BRITISH MEDICAL JOURNAL, 2013, 346
  • [42] MODELING PROSTATE CANCER RESPONSE TO CONTINUOUS VERSUS INTERMITTENT ANDROGEN ABLATION THERAPY
    Jain, Harsh Vardhan
    Friedman, Avner
    DISCRETE AND CONTINUOUS DYNAMICAL SYSTEMS-SERIES B, 2013, 18 (04): : 945 - 967
  • [43] Potential Benefits of Intermittent Androgen Suppression Therapy in the Treatment of Prostate Cancer: A Systematic Review of the Literature
    Abrahamsson, Per-Anders
    EUROPEAN UROLOGY, 2010, 57 (01) : 49 - 59
  • [44] Adverse Health Events Following Intermittent and Continuous Androgen Deprivation in Patients With Metastatic Prostate Cancer
    Hershman, Dawn L.
    Unger, Joseph M.
    Wright, Jason D.
    Ramsey, Scott
    Till, Cathee
    Tangen, Catherine M.
    Barlow, William E.
    Blanke, Charles
    Thompson, Ian M.
    Hussain, Maha
    JAMA ONCOLOGY, 2016, 2 (04) : 453 - 461
  • [45] Finnish multicenter study to compare intermittent and continuous androgen deprivation in patients with advanced prostate cancer
    Salonen, AJ
    Viitanen, J
    Ala-Opas, M
    Taari, K
    Tammela, TLJ
    JOURNAL OF UROLOGY, 2006, 175 (04): : 386 - 386
  • [46] Efficacy of Intermittent Androgen Deprivation Therapy vs Conventional Continuous Androgen Deprivation Therapy for Advanced Prostate Cancer: A Meta-analysis
    Tsai, Huei-Ting
    Penson, David F.
    Makambi, Kepher H.
    Lynch, John H.
    Van den Eeden, Stephen K.
    Potosky, Arnold L.
    UROLOGY, 2013, 82 (02) : 327 - 333
  • [47] Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma
    Sciarra, A
    Monti, S
    Gentile, V
    Mariotti, G
    Cardi, A
    Voria, G
    Lucera, R
    Di Silverio, F
    PROSTATE, 2003, 55 (03): : 168 - 179
  • [48] Risks of Serious Toxicities from Intermittent versus Continuous Androgen Deprivation Therapy for Advanced Prostate Cancer: A Population Based Study
    Tsai, Huei-Ting
    Pfeiffer, Ruth M.
    Philips, George K.
    Barac, Ana
    Fu, Alex Z.
    Penson, David F.
    Zhou, Yingjun
    Potosky, Arnold L.
    JOURNAL OF UROLOGY, 2017, 197 (05): : 1251 - 1257
  • [49] Intermittent versus continuous androgen deprivation therapy in hormone sensitive low volume metastatic prostate cancer with deep PSA response
    Hakeem, Muhammad Usman
    Jacques, Angela
    Ye, Linda
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 36 - 37
  • [50] PROSTATE CANCER Intermittent androgen deprivation-questions remain
    Keizman, Daniel
    Carducci, Michael A.
    NATURE REVIEWS UROLOGY, 2009, 6 (08) : 412 - 414